Evidence map›Paper›PMID 35891532›Full record

ReviewViruses2022

Think like a Virus: Toward Improving Nanovaccine Development against SARS-CoV-2.

Nura A Mohamed, Haissam Abou-Saleh, Hana A Mohamed, Mohammad A Al-Ghouti, Sergio Crovella, Luisa Zupin

Open access · goldAbstract readReview
In one paragraph

Review in Viruses, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.4field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 15 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

Nura A MohamedBiomedical Research Center (BRC), Qatar University, Doha P.O. Box 2713, Qatar.
Haissam Abou-SalehBiomedical Research Center (BRC), Qatar University, Doha P.O. Box 2713, Qatar.ORCID 0000-0003-3460-1413
Hana A MohamedBiological Science Program, Department of Biological and Environmental Sciences, College of Arts and Sciences, Qatar University, Doha P.O. Box 2713, Qatar.ORCID 0000-0001-9583-2050
Mohammad A Al-GhoutiEnvironmental Science Program, Department of Biological and Environmental Sciences, College of Arts and Sciences, Qatar University, Doha P.O. Box 2713, Qatar.ORCID 0000-0002-9943-1091
Sergio CrovellaBiological Science Program, Department of Biological and Environmental Sciences, College of Arts and Sciences, Qatar University, Doha P.O. Box 2713, Qatar.ORCID 0000-0001-8493-1168
Luisa ZupinInstitute for Maternal and Child Health IRCCS Burlo Garofolo, 34137 Trieste, Italy.ORCID 0000-0001-5886-9129
Qatar University · QAIRCCS Materno Infantile Burlo Garofolo · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

There is no doubt that infectious diseases present global impact on the economy, society, health, mental state, and even political aspects, causing a long-lasting dent, and the situation will surely worsen if and when the viral spread becomes out of control, as seen during the still ongoing coronavirus disease 2019 (COVID-19) pandemic. Despite the considerable achievements made in viral prevention and treatment, there are still significant challenges that can be overcome through careful understanding of the viral mechanism of action to establish common ground for innovating new preventative and treatment strategies. Viruses can be regarded as devil nanomachines, and one innovative approach to face and stop the spread of viral infections is the development of nanoparticles that can act similar to them as drug/vaccine carriers. Moreover, we can use the properties that different viruses have in designing nanoparticles that reassemble the virus conformational structures but that do not present the detrimental threats to human health that native viruses possess. This review discusses the current preventative strategies (i.e., vaccination) used in facing viral infections and the associated limitations, highlighting the importance of innovating new approaches to face viral infectious diseases and discussing the current nanoapplications in vaccine development and the challenges that still face the nanovaccine field.

Indexed as

COVID-19Viral VaccinesCOVID-19 VaccinesHumansPandemicsSARS-CoV-2COVID-19 VaccinesViral VaccinesnanotechnologySARS-CoV-2vaccine

Identifiers

PMID35891532
PMCPMC9318803
OpenAlexW4285804015

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.